"Factor VIII" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
| Descriptor ID |
D005169
|
| MeSH Number(s) |
D12.776.124.125.350 D23.119.350
|
| Concept/Terms |
Factor VIII- Factor VIII
- Factor 8
- Coagulation Factor VIII
- Thromboplastinogen
- Blood Coagulation Factor VIII
- Factor Eight
Hyatt-C- Hyatt-C
- Hyatt C
- HyattC
- Hyate-C
- Hyate C
- HyateC
|
Below are MeSH descriptors whose meaning is more general than "Factor VIII".
Below are MeSH descriptors whose meaning is more specific than "Factor VIII".
This graph shows the total number of publications written about "Factor VIII" by people in this website by year, and whether "Factor VIII" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 5 | 0 | 5 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 4 | 1 | 5 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor VIII" by people in Profiles.
-
Long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma-derived factor VIII (Koate) that contains ADAMTS13. Haemophilia. 2023 Nov; 29(6):1638-1645.
-
Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A. Haemophilia. 2023 Sep; 29(5):1234-1242.
-
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 08; 121(8):1079-1086.
-
Hemophilia: A Review of Perioperative Management for Cardiac Surgery. J Cardiothorac Vasc Anesth. 2022 01; 36(1):246-257.
-
A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. J Manag Care Spec Pharm. 2020 Oct; 26(10):1258-1265.
-
Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY?94-9027 for Severe Haemophilia?A: A Post Hoc Analysis. Adv Ther. 2020 06; 37(6):2763-2776.
-
Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.
-
Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-a pathway. Blood. 2018 09 06; 132(10):1064-1074.
-
Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost. 2018 04; 16(4):778-790.
-
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 01; 16(1):39-43.